Clinical trials: Benign Hyperplasia of Prostate
Benign Prostatic Hyperplasia
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
This study is designed to demonstrate the safety and efficacy of a second transrectal intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia (BPH) who previously received an injection of NX-1207…
- Trial name
- NCT01438775
- Testing
- NX-1207
- Where
- 28 sites in United States
- Volunteers
- 192 people
- Sponsor
- Nymox Corporation
Benign Prostate Hyperplasia
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
The study objectives are to demonstrate the efficacy and safety of the Medi-Tate iTIND as compared to control group (catheter only).
- Trial name
- NCT02506465
- Testing
- iTIND
- Where
- 13 sites in United States, Canada
- Volunteers
- 185 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
AVODART(Dutasteride) Post-marketing Surveillance(PMS)
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information
- Trial name
- AVO PMS (NCT01299571)
- Testing
- Dutasteride
- Where
- South Korea
- Volunteers
- 3,977 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia (BPH)
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm system in BPH treatment in China Rezūm RWS study
- Trial name
- NCT04823221
- Testing
- Rezūm System
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia, Localized Prostate Cancer
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
The goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are…
- Trial name
- NCT06051942
- Testing
- Robotic Waterjet Treatment
- Where
- 6 sites in United States, Hong Kong and 2 more
- Volunteers
- 125 people
- Sponsor
- PROCEPT BioRobotics
BPH, Prostate Hyperplasia
MRI Guided Transrectal Prostate Laser Ablation for Benign Prostatic Hypertrophy (BPH)
Over 100,000 BPH procedures are performed annually in the US. The purpose of this study is to evaluate the effectiveness of performing MRI guided transrectal laser ablation using a 980 nm laser (VisualaseTM by Medtronic, Inc., a…
- Conditions
- BPH, Prostate Hyperplasia, Urinary Frequency/Urgency
- Trial name
- NCT03131544
- Testing
- MRI Guided Transrectal Periuretheral Transitional Zone Ablation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Prostate Laser Center, PLLC
Benign Prostatic Hyperplasia
A Study to Assess the Effect of Fucoidan on Prostate Health in Males With Benign Prostatic Hyperplasia
The present study is a randomized, double-blind, placebo-controlled study. Approximately 125 individuals will be screened, and considering a screening failure rate of 20%, at least 100 will be randomized in a ratio of 1:1 to…
- Trial name
- NCT06487871
- Testing
- Fucoidan extracted from Undaria pinnatifida (UPF)
- Where
- 6 sites in India
- Volunteers
- 95 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Benign Prostatic Hyperplasia
Optilume™ BPH Catheter System in Men With Symptomatic BPH
PINNACLE is a prospective, multi-center, randomized control clinical trial to establish the safety and efficacy of the Optilume™ BPH Catheter System in the treatment of benign prostatic hyperplasia (BPH)
- Trial name
- PINNACLE (NCT04131907)
- Testing
- Optilume BPH Catheter System
- Where
- 21 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Urotronic Inc.
Neoplasms, Prostate
ARI103094-Follow-Up Study for REDUCE Study Subjects
ARI103094 is a follow-up study in adult male subjects who have received investigational product (either dutasteride or placebo) in the REDUCE Study (REduction by DUasteride of prostate Cancer Events), ARI40006, A Randomized…
- Trial name
- NCT00883909
- Testing
- dutasteride
- Where
- 267 sites in United States, Argentina and 10 more
- Volunteers
- 2,795 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
The Zenflow Spring System Feasibility and Safety Study
This is a First in Human study to assess the feasibility, safety and effectiveness of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- ZEST (NCT02786290)
- Testing
- Zenflow Spring System
- Where
- 3 sites in Bulgaria, New Zealand
- Volunteers
- 30 people
- Sponsor
- Zenflow, Inc.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Benign Prostatic Hyperplasia (BPH)
A Multi-center, International Prospective Follow up Study
The study objective is to assess the safety and efficacy of iTind three to five years following treatment.
- Trial name
- NCT04579913
- Testing
- Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
- Where
- 5 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Randomized, double-blind, placebo-controlled study with two treatment arms (Tamsulosin OCAS 0.4 mg \& placebo). The study comprises a 2-week placebo run-in followed by a 12-week treatment period.
- Trial name
- NCT00379067
- Testing
- Tamsulosin OCAS
- Volunteers
- 882 people
- Sponsor
- Astellas Pharma Inc
BPH
Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH
A total of up to 200 Symptomatic BPH subjects subjects will be enrolled into the study. Study duration will be 12 months post implantation with a follow-up visits at Year 2 and Year 3.
- Trial name
- MT-06 (NCT03395522)
- Testing
- iTind
- Where
- 12 sites in Australia, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Medi-Tate Ltd.
Benign Prostatic Hyperplasia
Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate
The purpose of this ex-vivo study is to evaluate the insertion procedure for the ProstaPlant implant in human prostates and the support that it supplies to the prostate.
- Trial name
- NCT00468026
- Testing
- ProstaPlant Stent
- Where
- Israel
- Sponsor
- ProstaPlant Urology System Ltd.
LUTS, Benign Prostatic Hyperplasia
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02447367
- Testing
- JLP-1207(Fasted), JLP-1207(Fed)
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia (BPH)
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00970632
- Testing
- Tadalafil 5 mg, Tamsulosin
- Where
- 44 sites in Australia, Austria and 8 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
- Trial name
- BREEZE (NCT04987138)
- Testing
- Zenflow Spring System
- Where
- 7 sites in United States
- Volunteers
- 279 people
- Sponsor
- Zenflow, Inc.
Prostatic Hyperplasia
Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia
The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings.
- Trial name
- NCT02245529
- Testing
- Tamsulosin
- Volunteers
- 982 people
- Sponsor
- Boehringer Ingelheim